CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 114 enrolled
Drug / intervention
Peginterferon alfa-2a +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02726022
NCT02726022N/ACompleted
CompareCT.gov

A Quality of Life Study of PEGASYS® (Peginterferon-Alfa2a) in Combination With COPEGUS® (Ribavirin) in Patients With Chronic Hepatitis C and Persistently Normal ALT Levels

Hoffmann-La Roche·observational·Posted Apr 1, 2016·Updated Aug 15, 2016

In Brief

An observational study evaluating Peginterferon alfa-2a and Ribavirin for Hepatitis C, Chronic. Completed, enrolled 114 participants across 10 sites.

Detailed Summary

Participants with Chronic Hepatitis C (CHC) and normal ALT, who have been under treatment with peginterferon alfa-2a and ribavirin for at least 4 weeks, will be enrolled into this non-interventional, open-label study. The primary aim is to evaluate quality of life according to the 36-Item Short-Form Health Survey (SF-36) questionnaire, modified for the Greek population.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C, Chronic
CountriesGreece
Collaborators--

Timeline

N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 1, 2016
Enrollment StartFeb 1, 2007
Primary CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 10.3 years ago

Interventions

Peginterferon alfa-2adrug

As per treating physician discretion and according to summary of product characteristics.

Ribavirindrug

As per treating physician discretion and according to summary of product characteristics.